<DOC>
	<DOCNO>NCT01376427</DOCNO>
	<brief_summary>This study propose provide adequate treatment base current scientific evidence elderly patient ALL Bcr / Abl positive . To determine whether low-dose chemotherapy associate imatinib dasatinib acceptable tolerability elderly patient . To determine whether association increase rate quality referral result literature imatinib monotherapy elderly patient</brief_summary>
	<brief_title>Treatment Acute Lymphoblastic Leukemia Ph ' ( BCR / ABL ) Positive Patients Aged &gt; 55 Years</brief_title>
	<detailed_description>Prephase ( day -5 -1 ) Dexamethasone 10 mg/m2 bolus day EV 5 day ( -5 -1 ) . Intrathecal treatment ( diagnosis prophylactic / therapeutic ) -5 day : Methotrexate 12 mg Systemic treatment : - Imatinib 400 mg daily continuous VO . - Vincristine ( VCR ) 1 mg ( absolute dose ) EV 1 , 8 , 15 22 . - Dexamethasone ( DEX ) : 10 mg/m2 EV , IM PO day 1-2 , 8-9 day 15-16 , 22-23. . Intrathecal chemotherapy : Triple therapy administer methotrexate ( MTX ) , cytosine arabinoside ( ARA-C ) hydrocortisone , day 1 , 8 , 15 22 ( five dos total prophylactic prophase induction ) : MTX 12 mg ARA-C 40 mg Dexamethasone 4 mg Maintenance first year start full recovery induction complete reassessment disease ( include mielograma Bcr-Abl/Abl Bcr-Abl/Gus ratio peripheral blood ) last one year time complete remission . The basic treatment include imatinib 400 mg / day ( dasatinib ) , mercaptopurine dose 50 mg/m2 PO day methotrexate 20 mg/m2 IM weekly . One week every 3 month maintenance treatment add `` mini-reinduction '' consist - VCR : 1 mg ( absolute dose ) , i.v. , day 1 . - Dexamethasone 40 mg / day , i.v . p.o. , day 1-2 . - consider dos triple intrathecal therapy . Reinduction practice first year remission , total 4 quarterly . Maintenance treatment second year After first year maintenance perform complete reassessment disease ( include myelogram ) patient remain complete remission maintenance continue ( without reinduction ) two year time diagnosis . Maintenance treatment third year During third year complete remission imatinib administer alone ( dasatinib</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Adults 55 year diagnose acute lymphoblastic leukemia Ph 'positive ( Bcr / Abl positive ) previously untreated 1 . Other LAL negative ( 9 ; 22 ) Bcr / Abl . 2. biphenotypic acute leukemia bilinear ( 9 ; 22 ) . 3. blast crisis chronic myeloid leukemia progression polychemotherapy treatment ( include alloBMT ) inhibitor tyrosine kinase . The criteria exclusion treatment ( patient record ) follow 4 . General condition affect ( grade 3 4 WHO scale ) , attributable LAL . 5 . Lack consent patient use clinical</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>